InfectoPharm Invests in AudioCure to Advance Innovative Hearing Loss Therapy

HEPPENHEIM, Germany & BERLIN--(BUSINESS WIRE)--Feb 13, 2025--

There is currently no drug approved worldwide for the treatment of sudden hearing loss. However, preclinical and clinical phase-1-studies with the innovative drug candidate AC102 have been promising.AudioCure Pharma, a Berlin-based start-up supported by investors, is driving forward research and development. Now,InfectoPharm, a successful medium-sized company, is joining as a new and essential competence partner.The Heppenheim-based ENT specialist is leading the new round of financing and is strengthening the existing group of investors, which includes main investorMED-ELand seed investorHigh-Tech Gründerfonds(HTGF). The main goal of the collaboration is to successfully advance the clinical development of AC102, a drug for sudden hearing loss.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250213622345/en/

The investors are not only providing AudioCure with financial support for the development of new drugs, but are also expanding its knowledge base with their respective scientific and commercial expertise. MED-EL Medical-Electronics and InfectoPharm Arzneimittel are contributing their extensive expertise gained from over 30 years in the ENT field. Dr Reimar Schlingensiepen, CEO of AudioCure, is delighted: ‘AudioCure and its partners complement each other perfectly. Together, we can advance our research and development activities even further and develop innovative active ingredients. We are also pleased to now have InfectoPharm's many years of experience in the pharmaceutical industry on board.’

The additional funds will mainly be used for the further development of the drug candidate AC102. This has already been successfully tested for tolerability and safety in humans and is currently being investigated in a Europe-wide phase-2-study for its efficacy in sudden hearing loss patients. In preclinical models of hearing loss, AC102 was able to restore hearing almost completely, exceeding the efficacy of conventional corticosteroid therapies. Philipp Zöller, managing partner of InfectoPharm Arzneimittel und Consilium GmbH, comments: ‘As a specialist in pharmaceutical products for ear, nose and throat conditions, we are very familiar with the difficult situation of sudden hearing loss patients. We are therefore delighted to be able to support the development of a potentially groundbreaking drug like AC102, both financially and with our expertise, as part of the AudioCure investor team.’

Investors in the current financing round with AudioCure Management. From left to right: Philipp Zöller (CEO InfectoPharm), Prof Hans Rommelspacher (founder AudioCure), Dr Reimar Schlingensiepen (CEO AudioCure), Dr Ingeborg Hochmair (CEO MED-EL) and Dr Christian Kannemeier (Senior Investment Manager HTGF). Copyright: AudioCure.

KYOTO, Japan--(BUSINESS WIRE)--Jun 15, 2026--

Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) announces a new collaboration with Synopsys, Inc., enabling users of Synopsys' simulation tools to navigate directly to Murata's website to access and download the latest high-performance simulation models from Murata. The collaboration covers Synopsys' 3D electromagnetic field analysis tool Ansys HFSS™ and thermal analysis tool Ansys Icepak®, and marks a significant step toward streamlining the simulation workflow for electronic circuit designers. Murata is also the first company to offer passive component simulation models via Ansys Icepak*.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615241645/en/

As demand for high-speed, high-capacity communications continues to grow, electronic circuit design has become increasingly complex. Engineers must now account for a range of physical phenomena, from electromagnetic interference (EMI) to component heat generation, within a single design. Addressing these challenges early in the design process is critical; overlooking them can trigger costly redesigns, extend development timelines, and drive up prototyping expenses. This has placed greater pressure on electronic component suppliers to provide ready-to-use, high-quality simulation models that are compatible with the tools engineers already rely on.

Developing accurate models for electromagnetic and thermal analysis is inherently challenging, as both electromagnetic behavior and temperature distribution shift considerably depending on design conditions. Murata's vertically integrated approach, spanning raw material development and manufacturing through to final product processing, enables the company to draw on an extensive proprietary dataset, resulting in simulation models that closely reflect real-world component performance.

The models are compatible with Ansys 2026 R1. Ansys HFSS supports electromagnetic field analysis and covers Murata's RF inductors and multilayer ceramic capacitors (MLCCs), while Ansys Icepak supports thermal analysis and covers Murata's power inductors.

Looking ahead, Murata will continue to deepen its collaboration with Synopsys, expanding its model lineup to support more advanced and efficient electronic design.

The following data is available for download from Murata's website:
Electromagnetic field analysis data for Ansys HFSS — RF inductors
Electromagnetic field analysis data for Ansys HFSS — MLCCs
Thermal analysis data for Ansys Icepak — Power inductors

For product data inquiries, please contact Murata regarding inductor products here, or capacitor products here.

Notes:
*Based on Murata research as of June 15, 2026.

About Synopsys

Synopsys, Inc. (Nasdaq: SNPS) is the leader in engineering solutions from silicon to systems, enabling customers to rapidly innovate AI-powered products. We deliver industry-leading silicon design, IP, simulation and analysis solutions, and design services. We partner closely with our customers across a wide range of industries to maximize their R&D capability and productivity, powering innovation today that ignites the ingenuity of tomorrow. Learn more at www.synopsys.com.

© 2026 Synopsys, Inc. All rights reserved. Synopsys, Ansys, the Synopsys and Ansys logos, and other Synopsys trademarks are available athttps://www.synopsys.com/company/legal/trademarks-brands.html. Other company or product names may be trademarks of their respective owners.

About Murata

Murata Manufacturing Co., Ltd. is a worldwide leader in the design, manufacture and sale of ceramic-based passive electronic components & solutions, communication modules and power supply modules. Murata is committed to the development of advanced electronic materials and leading edge, multi-functional, high-density modules. The company has employees and manufacturing facilities throughout the world.

[Murata Manufacturing Co., Ltd.] New collaboration with Synopsys